• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Protein-associating with the carboxyl-terminal domain of ezrin (SCYL3)

ACP15210

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15210 Target NameSCYL3
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range2-742Protein LengthFull Length of Mature Protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8IZE3
Background Information
  • Uniprot Id

    Q8IZE3

  • Target Species

    Human

  • Target Name

    SCYL3

  • Target Full Name

    Protein-associating with the carboxyl-terminal domain of ezrin

  • Target Function

    May play a role in regulating cell adhesion/migration complexes in migrating cells.

  • Target Subcellular Location

    Cytoplasm. Golgi apparatus. Cell projection, lamellipodium. Note=Colocalized with EZR/VIL2, actin and CD44 in lamellipodia.

  • Target Protein Families

    Protein kinase superfamily

  • Target Tissue Specificity

    Ubiquitously expressed.

  • Target Synonyms

    Ezrin binding protein PACE 1 ; Ezrin-binding protein PACE-1; PACE 1 ; PACE1 ; PACE1_HUMAN; Protein associating with the carboxyl terminal domain of ezrin; Protein-associating with the carboxyl-terminal domain of ezrin; SCY1 like 3 (S. cerevisiae); SCY1 like 3; SCY1 like protein 3; SCY1 like pseudokinase 3; SCY1-like protein 3; SCYL 3; SCYL3

Inquire Recombinant Human Protein-associating with the carboxyl-terminal domain of ezrin (SCYL3) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification